ライフサイエンスコーパス: autoimmune pancreatitis

1 disease, type 1 diabetes mellitus (T1D), and autoimmune pancreatitis.

2 nsus was reached on the issue of subtypes of autoimmune pancreatitis.

3 s and development of new therapies for human autoimmune pancreatitis.

4 istics, course, and therapeutic responses in autoimmune pancreatitis.

5 n the rat, which we have termed experimental autoimmune pancreatitis.

6 imab can induce remission and maintenance of autoimmune pancreatitis.

7 (73.7% vs. 29.7%, p < 0.001) and coexisting autoimmune pancreatitis (52.6% vs. 0%, p < 0.001).

8 t amylase may play a role in pathogenesis of autoimmune pancreatitis (6) 2-(18F)-Fluro-2-deoxy-D-gluc

9 h obstructive jaundice (77%) associated with autoimmune pancreatitis (92%), increased serum IgG4 leve

10 Reviews of autoimmune pancreatitis, a newly described condition, pa

11 um immunoglobulin G4 (sIgG4) is a feature of autoimmune pancreatitis (AIP) and IgG4-associated cholan

12 To summarize the existing knowledge of autoimmune pancreatitis (AIP) and to review the progress

13 ted pancreatic bicarbonate concentrations in autoimmune pancreatitis (AIP) by restoring mislocalized

14 k trial of corticosteroids may differentiate autoimmune pancreatitis (AIP) from pancreatic cancer in

15 Autoimmune pancreatitis (AIP) has been divided into subt

16 BACKGROUND/OBJECTIVES: Autoimmune pancreatitis (AIP) is a diagnosis-challenging

17 Autoimmune pancreatitis (AIP) is a heterogeneous autoimm

18 Autoimmune pancreatitis (AIP) is a rare and underdiagnos

19 Autoimmune pancreatitis (AIP) is an increasingly recogni

20 Autoimmune pancreatitis (AIP) is the pancreatic manifest

21 Autoimmune pancreatitis (AIP) underlies 5%-11% of cases

22 tify current modalities for the diagnosis of autoimmune pancreatitis (AIP) with the objective of esta

23 Autoimmune pancreatitis (AIP), a recently defined diseas

24 is known about the pathogenic mechanisms of autoimmune pancreatitis (AIP), an increasingly recognize

25 m retrospective case series of patients with autoimmune pancreatitis (AIP), and follow-up periods hav

26 ith pancreatic cancer, chronic pancreatitis, autoimmune pancreatitis (AIP), and healthy controls (N).

27 treatment, and at follow-up in patients with autoimmune pancreatitis (AIP).

28 re part of a spectrum of disorders including autoimmune pancreatitis and inflammatory pseudotumor.

29 patients, which may indicate an overlap with autoimmune pancreatitis and possible responsiveness to s

30 e the degree of inflammation and fibrosis in autoimmune pancreatitis and to monitor response to stero

31 e and the Cochrane Library, using the terms 'autoimmune pancreatitis' and 'pancreatic resection' and

32 ciations with inflammatory bowel disease and autoimmune pancreatitis, and medical therapy are discuss

33 ids rapidly reduce symptoms in patients with autoimmune pancreatitis, and micronutrient therapy to co

34 inical diagnostic and therapeutic aspects of autoimmune pancreatitis; and information on feeding stra

35 Furthermore, the complexities of diagnosing autoimmune pancreatitis are being recognized.

36 rts outlining the complexity in diagnosis of autoimmune pancreatitis; emerging roles of endoscopic ul

37 The clinical description of autoimmune pancreatitis has led to the realization that

38 Clinical description and studies of autoimmune pancreatitis have led to the realization that

39 sed with primary sclerosing cholangitis have autoimmune pancreatitis in association with primary scle

40 st that gastric H. pylori infection triggers autoimmune pancreatitis in genetically predisposed indiv

41 Features that suggest autoimmune pancreatitis include focal or diffuse pancrea

42 tive descriptive evaluation of patients with autoimmune pancreatitis including dedicated radiology re

43 Autoimmune pancreatitis may belong to a multiorgan immun

44 sh patients with IgG4-associated cholangitis/autoimmune pancreatitis (n = 34) from those with primary

45 res of IgG4-RSD in these 4 patients included autoimmune pancreatitis, sclerosing cholangitis, lymphop

46 nfirms that in non-expert practice settings, autoimmune pancreatitis scoring systems with a focus on

47 pancreatic lesions of rats with experimental autoimmune pancreatitis were characterized histologicall

48 -82 years) with histopathologic diagnosis of autoimmune pancreatitis were examined.

49 ts with radiographic OR clinical features of autoimmune pancreatitis were initially identifiable (Mal

50 onic pancreatitis (early chronic, groove and autoimmune pancreatitis) were reviewed by 21 specialists

51 utility of published diagnostic criteria for autoimmune pancreatitis, when compared to the characteri